INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
LICENSE AGREEMENTLicense Agreement • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SERVICES AGREEMENTServices Agreement • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
This Services Agreement (the “Agreement”), dated as of July 16, 2014 (the “Effective Date”), is made by and between Caribou Biosciences, Inc., a Delaware corporation (“Caribou”) and Intellia, LLC, a Delaware limited liability company (“Intellia”) Each of Caribou and Intellia may be referred to herein as a “Party” or together as the “Parties.”
ADDENDUM TO LICENSE AGREEMENTLicense Agreement • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances
This Addendum to License Agreement (this Addendum”) is made and entered into as of February 2, 2016 (the “Addendum Date”), and amends that certain License Agreement dated as of July 16, 2014, as amended or supplemented through the Amendment Date (the “License Agreement”), by and between Caribou Biosciences, Inc. (“Caribou”) and Intellia Therapeutics, Inc. (as successor in interest and assignee of Intellia, LLC, and herein thereafter referred to as “Intellia”). Each of Caribou and Intellia may be referred to herein as a “Party” or together as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement.
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances
This Amendment No. 1 to License Agreement (this “Amendment”) is made and entered into as of February 2, 2016 (the “Amendment Date”), and amends that certain License Agreement, dated as of July 16, 2014, as amended or supplemented through the Amendment Date (the “License Agreement”), by and between Caribou Biosciences, Inc. (“Caribou”) and Intellia Therapeutics, Inc. (“Intellia”) (as successor in interest to Intellia, LLC under the License Agreement). Each of Caribou and Intellia may be referred to herein as a “Party” or together as “Parties.” Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement.
LEASE by and between BMR-SIDNEY RESEARCH CAMPUS LLC, a Delaware limited liability company and INTELLIA THERAPEUTICS, INC., a Delaware corporationLease • April 11th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances
THIS LEASE (this “Lease”) is entered into as of this 6th day of January, 2016 (the “Execution Date”), by and between BMR-Sidney Research Campus LLC, a Delaware limited liability company (“Landlord”), and Intellia Therapeutics, Inc., a Delaware corporation (“Tenant”).
